The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness

BJU International

Volumn 104, Issue 4, 2009, Pages 486-489

  Morote, Juan ^a   Ramirez, Cristobal ^a   Gómez, Esther ^a   Planas, Jacques ^a   Raventós, Carles X ^a   Torres, Inés M De ^a   Catalán, Roberto ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Aggressiveness; Free testosterone; Prostate cancer risk; Testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CORRELATION ANALYSIS; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK FACTOR; STATISTICAL ANALYSIS; TESTOSTERONE BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY; TUMOR GROWTH; BLOOD; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

AGED; BIOPSY, NEEDLE; DIGITAL RECTAL EXAMINATION; DISEASE PROGRESSION; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 69849101398     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08378.x     Document Type: Article

References (21)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide , Version 2.0. Lyon, France: IARC Press, 2004
2. Bostwick DG, Burke HB, Djakiew D et al. Human prostate cancer risk factors. Cancer 2004; 101 : 2371-2490
3. Hsing AW. Hormones and prostate cancer: what's next ? Epidemiol Rev 2001; 23 : 42-58
4. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004; 92 : 237-253
5. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 : 215-224
6. Canby-Hagino E, Hernandez J, Brand TC, Thompson I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol 2007; 51 : 27-33
7. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350 : 482-492
8. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006; 50 : 935-939
9. Morgentaler A. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol 2007; 52 : 623-625
10. Hoffman M, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163 : 824-827
11. Schatzl G, Madersbacher S, Thurridl T et al. High-grade prostate cancer isassociated with low serum testosterone levels. Prostate 2001; 47 : 52-58
12. San Francisco IF, Regan MM, Dewolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 2006; 175 : 1341-1346
13. Massengill JC, Sun L, Moul JW et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169 : 1670-1675
14. Teloken C, Da Ros CT, Caraver F et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005; 174 : 2178-2180
15. Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997; 20 : 605-608
16. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology 2006; 68 : 1263-1267
17. Karamanolakis D, Lambou T, Bogdanos J et al. Serum testosterone. A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (greater than or 3.0 and less than 10.0 ng/ ml). Anticancer Res 2006; 26: 3159-3166
18. Rhoden EL, Riedner CH, Morgentaler A. The ratio of serum testosterone-toprostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 2008; 179: 1741-1745
19. Remzi M, Fong YK, Dobrovits M et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate. J Urol 2005; 174: 1256-1261
20. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974 (Pubitemid 28445094)
21. Roddam AW, Allen NE, Appleby P; the Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-183